Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAR 422459

Next Previous
Drug Profile

SAR 422459

Alternative Names: ABCA4 gene therapy; ATP-binding transporter gene therapy; SAR-422459; Stargardt disease gene therapy - Oxford BioMedica/Sanofi; StarGen

Latest Information Update: 13 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oxford BioMedica
  • Developer Oxford BioMedica; Sanofi
  • Class Gene therapies
  • Mechanism of Action ATP-binding cassette transporter replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eye disorders
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Stargardt disease

Most Recent Events

  • 13 Nov 2019 SAR 422459 is available for licensing as of 31 Oct 2019. https://www.sanofi.com/
  • 27 Sep 2019 Suspended - Phase-II clinical trials in Stargardt disease in USA, Netherlands, Italy, France (Intraocular) (NCT01367444)
  • 26 Sep 2019 Sanofi terminates a phase I/II trial for Stargardt disease 1 in USA, France, Netherlands and Italy due to review of clinical development plans and priorities (Intraocular) (NCT01367444)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top